Literature DB >> 29940632

Expression and significance of Ki-67 in lung cancer.

Roxana Folescu1, Codrina Mihaela Levai, Mirela Loredana Grigoraş, Teodora Smaranda Arghirescu, Ioana Cristina Talpoş, Ciprian Mihai Gîndac, Carmen Lăcrămioara Zamfir, Vladimir Poroch, Mirella Dorina Anghel.   

Abstract

Ki-67 parameter is a proliferation marker in malignant tumors. The increased proliferation activity and the decreased prognosis in lung cancer determined us to investigate different parameters connected to the tumor's aggression, such as cellularity, Ki-67 positivity rate, and proliferating cell nuclear antigen (PCNA). We evaluated the proliferative activity in 62 primary lung tumors by determining the cell's percentage of Ki-67 and immunoreactive PCNA (using MIB-1 and PCNA monoclonal antibodies), classifying Ki-67 and PCNA immunoreactivity into three score groups. The results obtained emphasized a linkage between Ki-67 score with the histological tumor subtype, tumor cellularity and degree of differentiation and with other proliferation immunohistochemistry (IHC) markers, such as p53 cellular tumor antigen. The tumor's cellularity, the Ki-67 positivity rate and PCNA, together with the clinical stage and the histological differentiation bring extra pieces of useful information in order to anticipate the evolution and the prognosis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29940632

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  10 in total

1.  Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma.

Authors:  Hongjin Chen; Ruixue Xia; Long Jiang; Yong Zhou; Haojun Xu; Weiwei Peng; Chengyun Yao; Guoren Zhou; Yijie Zhang; Hongping Xia; Yongsheng Wang
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

2.  Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report.

Authors:  Yunpeng Liu; Zhiru Gao; Chengbin Zhang; Xing Liu; Zihao Liu; Xingyu Lin; Benxin Qian; Fukang Jin; Guoguang Shao; Zhiguang Yang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

3.  Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis.

Authors:  Pengyi Guo; Tinghui Xu; Ying Jiang; Wenming Shen
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

4.  CEA-Ki-67- Pathologic Subtype: An Adjunct Factor for Refining Prognosis in Stage I Pulmonary Adenocarcinoma.

Authors:  Dongzhi Yu; Yanbin Sun; Michael A McNutt; Shun Xu
Journal:  Front Surg       Date:  2022-04-25

5.  Mxi1 participates in the progression of lung cancer via the microRNA-300/KLF9/GADD34 Axis.

Authors:  Yujie Lei; Yunchao Huang; Jianbin Lin; Shihui Sun; Keda Che; Junting Shen; Jun Liao; Yangming Chen; Kai Chen; Zhaoxian Lin; Xing Lin
Journal:  Cell Death Dis       Date:  2022-05-02       Impact factor: 8.469

6.  Evaluation of FIB-4, NFS, APRI and Liver Function Tests as Predictors for SARS-CoV-2 Infection in the Elderly Population: A Matched Case-Control Analysis.

Authors:  Mirela Loredana Grigoras; Ioana Mihaela Citu; Cosmin Citu; Veronica Daniela Chiriac; Florin Gorun; Mihaela Codrina Levai; Diana Manolescu; Ovidiu Rosca; Felix Bratosin; Srivathsava Gurumurthy; Prima Hapsari Wulandari; Octavian Marius Cretu
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

7.  Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I-III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity.

Authors:  Junkai Feng; Menglong Hu; Zongkuo Li; Guiming Hu; Yuting Han; Yan Zhang; Min Zhang; Jingli Ren
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

8.  Expression of MTERF3 gene in breast carcinoma and the relationship with clinicopathological characteristics.

Authors:  Wei-Si Wang; Jia-Ji Zi; Mei-Tao Sun; Wen Mei; Su-Fen Li; Na Yang; Zai-Yi Fei; Ruo-Peng Zhang; Min Yu; Wei Xiong
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

9.  The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease.

Authors:  Bei Wang; Xiaoyan Zhang; Huang Chen; Lei Yang; Jie Li; Fei Xiao; Chaoyang Liang; Dingrong Zhong
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

10.  Relationship Between Ultrasound Features and Ki-67 Labeling Index of Soft Tissue Sarcoma.

Authors:  Pingping Wang; Hai Li; Yu Hu; Xiaojing Peng; Xinhua Ye; Di Xu; Ao Li
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.